Harrison Bay Life Sciences Announces Commercialization Launch

Launching, marketing, and supporting medical devices in the U.S. market can be a daunting, expensive, and time-consuming enterprise, particularly for companies that may not have an existing presence in the U.S.

Harrison Bay Life Sciences (HBLS), headquartered in Chattanooga, Tennessee, recently announced the growth of its business that aids medical device companies seeking a commercialization partner who can bring innovative medical products and services to market.

HBLS’s unique infrastructure and experienced team provide medical device startup companies with everything they need to successfully achieve and maintain profitability throughout a product’s lifecycle. HBLS will guide products through market analysis and market development; clinical trials and FDA approval; market entry and promotion; logistics, delivery, and inventory management; and provide exceptional clinical support.

Companies will be able to leverage HBLS’ existing relationships and credentials with hospitals, outpatient surgery centers, group purchasing organizations, and physician practices. They’ll also be able to take advantage of HBLS’ proprietary logistics and fulfillment systems, military-grade cybersecurity protocols and consulting, and remote case/procedure support through advanced remote imaging technologies.

Real-Time Imaging Services & Remote Procedure Support
HBLS’s clients benefit from its remote case/procedure support imaging tool, which allows remote users 360° views of a surgical suite as if they were present. The proprietary software merges and renders simultaneous realities without latency, offering meaningful collaboration around the world. It also features built-in 4D, AR and AI capabilities, including adaptive visualization.

This allows technicians to support sophisticated medical devices and physicians remotely, without the need for travel or physically accessing medical facilities. This will become increasingly important in the post-COVID-19 era, as more medical facilities will increasingly limit access, and as there continues to be local shortages of available medical experts and technicians.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version